Royalty Pharma Q2 Royalty Receipts up 14% to $768M; raises FY 2026 guidance

Royalty Pharma plc

Q2 Royalty Receipts $768M (+14% YoY); Portfolio Receipts $773M (+6%).
Raised FY 2026 Portfolio Receipts guidance to $3.4B-$3.5B (from $3.325B-$3.45B).
Acquired royalty on AstraZeneca's cliramitug for up to $425M ($125M upfront) in July.
Capital Deployment YTD $1.1B; announced transactions value $1.7B.
Paid Q2 dividend $0.235/share; repurchased $45M in shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.